Enliven Historical Cash Flow
| ELVN Stock | 25.41 1.06 4.35% |
Analysis of Enliven Therapeutics cash flow over time is an excellent tool to project Enliven Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 54.9 M or Capital Expenditures of 244 K as it is a great indicator of Enliven Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Enliven Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Enliven Therapeutics is a good buy for the upcoming year.
Enliven |
About Enliven Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Enliven balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Enliven's non-liquid assets can be easily converted into cash.
Enliven Therapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Enliven Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Enliven Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.At this time, Enliven Therapeutics' Change In Cash is very stable compared to the past year. As of the 29th of November 2024, Capital Expenditures is likely to grow to about 244 K, though Free Cash Flow is likely to grow to (58.3 M).
| 2021 | 2023 | 2024 (projected) | Change To Netincome | 1.9M | 1.7M | 1.6M | Issuance Of Capital Stock | 690K | 531.9K | 505.3K |
Enliven Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Enliven Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Enliven Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.4M) | 121.5M | (20.3M) | (34.5M) | 24.6M | 25.8M | |
| Free Cash Flow | (22.0M) | (9.0M) | (19.3M) | (32.7M) | (61.4M) | (58.3M) | |
| Change In Working Capital | 673K | 583K | 3.6M | 438K | 1.4M | 1.2M | |
| Begin Period Cash Flow | 7.4M | 8.9M | 130.4M | 110.1M | 75.6M | 54.9M | |
| Other Non Cash Items | 196K | 9.7M | 3.8M | 1.7M | (4.3M) | (4.1M) | |
| Capital Expenditures | 140K | 461K | 191K | 612K | 149K | 244.0K | |
| Total Cash From Operating Activities | (21.9M) | (8.5M) | (19.1M) | (32.1M) | (61.3M) | (58.2M) | |
| Total Cash From Financing Activities | 43.6M | 130.5M | (1.0M) | (1.8M) | 234.3M | 246.0M | |
| End Period Cash Flow | 4.9M | 130.4M | 110.1M | 75.6M | 100.2M | 68.9M | |
| Stock Based Compensation | 899K | 130K | 1.9M | 3.2M | 12.9M | 13.6M | |
| Other Cashflows From Financing Activities | (24.1M) | 260.9M | (1.2M) | (1.8M) | 234.3M | 246.0M | |
| Net Income | (23.5M) | (19.0M) | (24.7M) | (37.7M) | (71.6M) | (68.0M) |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.46 | HLN | Haleon plc | PairCorr |
| 0.44 | ANRO | Alto Neuroscience, | PairCorr |
| 0.42 | BA | Boeing Fiscal Year End 29th of January 2025 | PairCorr |
| 0.4 | SHG | Shinhan Financial | PairCorr |
| 0.37 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.